Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Herstal – page 16

1 407 clinical trials in Herstal, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Herstal at a glance
1 407
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 407 trials in Herstal

Open in trial search

Evaluation of Long-Term Safety and Efficacy of Litifilimab in Adults with Active Systemic Lupus Erythematosus: A Phase 3 Multicenter, Randomized, Dose-Blind Study

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Litifilimab
  • Sponsor:Biogen Idec Research Limited

Efficacy and Safety of Subcutaneous Belimumab in Adults with Connective Tissue Disease-Associated Interstitial Lung Disease

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Belimumab
  • Sponsor:Glaxosmithkline Research & Development Limited

A study testing how well AZD4144 works and how safe it is for adults with acute kidney injury caused by sepsis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:AZD4144
  • Sponsor:AstraZeneca AB

A Study of Cemiplimab Given Before Surgery in Patients with Early Stage Merkel Cell Carcinoma of the Skin

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

A Study of Pembrolizumab and Radiotherapy for Patients with Early-Stage Favorable Classic Hodgkin Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:University Of Cologne

A Study of Camizestrant and Ribociclib for Patients with Hormone Receptor-Positive Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Camizestrant
  • Sponsor:Medica Scientia Innovation Research S.L.

Cardiac failure+1

Recruiting

A study of finerenone with standard treatment for children and young adults from birth to 18 years with heart failure and left ventricular systolic dysfunction

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Finerenone
  • Sponsor:Bayer AG

Cardiac failure+1

Recruiting

A study of finerenone added to standard treatment in children aged 6 months to under 18 years with heart failure and reduced left heart pumping function

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Finerenone
  • Sponsor:Bayer AG

A study of coramitug compared to placebo for people with heart failure caused by transthyretin amyloid cardiomyopathy

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Coramitug
  • Sponsor:Novo Nordisk A/S

Study of glepaglutide compared to placebo for patients with short bowel syndrome with intestinal failure

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Glepaglutide
  • Sponsor:Zealand Pharma A/S

Breast cancer+1

Recruiting

Study of inavolisib and fulvestrant for patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Fulvestrant
  • Sponsor:F. Hoffmann-La Roche AG

A study of bleximenib combined with intensive chemotherapy for adults with newly diagnosed acute myeloid leukemia with specific genetic changes.

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bleximenib
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Herstal

What the registry says about research in the country

01 Immune System Diseases

Clinical research in Herstal is focused on immune system diseases, with all currently listed studies centered on atopic dermatitis. These trials are examining whether a new treatment approach can better control symptoms and improve everyday skin health for people living with moderate-to-severe disease.

  • Testing a new therapy for better control of atopic dermatitis
  • Comparing treatment effectiveness against placebo
  • Assessing improvements in skin signs and symptom severity

The research program in this Belgian city is aimed at understanding how well treatment options work for patients who need stronger support than standard care alone.

02 Atopic Dermatitis

The main disease under study is atopic dermatitis, a chronic inflammatory skin condition that can cause itching, redness, and discomfort. Current trials are looking at whether a targeted therapy can offer meaningful relief, either on its own or alongside common skin treatments.

  • Evaluating a new option for moderate-to-severe atopic dermatitis
  • Studying treatment used with topical corticosteroids and topical calcineurin inhibitors
  • Measuring changes in disease control and visible skin improvement
  • Supportive research for patients seeking better symptom management

These studies are designed to help clarify whether newer approaches can improve outcomes for people whose skin disease remains difficult to manage.

03 Topical Combination Treatment Research

Another important area of research is the use of topical corticosteroids and topical calcineurin inhibitors alongside investigational therapy. This work is focused on evaluating how combination treatment may improve relief and disease control compared with standard topical care alone.

  • Studying combination care for moderate-to-severe atopic dermatitis
  • Assessing whether added therapy improves overall response
  • Looking at clinical signs and severity over time

The trials in Belgium reflect a practical clinical question: whether pairing new and established treatments can lead to better outcomes for patients.

04 Therapeutic Innovation in Skin Inflammation

The local trial landscape is small but concentrated, with all active studies exploring a single inflammatory skin condition. This makes Herstal a focused site for research on newer therapies aimed at reducing the burden of persistent eczema symptoms.

  • Exploring a new treatment for inflammatory skin disease
  • Comparing benefit against standard control approaches
  • Helping define better options for routine patient care

Overall, the studies are centered on improving treatment effectiveness and expanding options for people living with difficult-to-treat skin inflammation.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.